Partner News | Published: Monday, May 15, 2023
egnite, Inc., a leading digital health company for cardiovascular care and a MedAxiom partner, announces the expansion of its portfolio with the integration of a custom module designed to help identify patients with atrial fibrillation (AF), deemed to be at elevated risk of stroke and bleeding, who are potentially eligible for left atrial appendage closure (LAAC) therapy. This treatment is an alternative to blood thinners proven to reduce the risk of stroke in patients with non-valvular AF, a widespread condition among the aging population in the US.
Developed in collaboration with a global leader in medical device technologies, this custom module is integrated into CardioCare, egnite’s flagship solution for health systems. The technology leverages egnite’s advanced data processing to scan over 1,700 hospital codes, identifying potential LAAC patients with high precision and delivering insights to inform targeted care.
By continuing to use our site, you agree to our Cookie Policy, Privacy Policy and Terms of Use.
